Page last updated: 2024-08-23

androstane-3,17-diol and Obesity, Morbid

androstane-3,17-diol has been researched along with Obesity, Morbid in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Du, J; Ge, M; Mizraji, K; Niu, C; Segall-Gutierrez, P; Stanczyk, FZ; Tilley, I1

Trials

1 trial(s) available for androstane-3,17-diol and Obesity, Morbid

ArticleYear
Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
    Contraception, 2012, Volume: 86, Issue:6

    Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Biomarkers; Body Mass Index; Contraceptive Agents, Female; Dehydroepiandrosterone Sulfate; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Sex Hormone-Binding Globulin; Subcutaneous Tissue; Testosterone; Time Factors; Young Adult

2012